drugset / Trial / NCT05156398
Efficacy and Safety Study of Rimegepant for the Preventative Treatment of Migraine in Pediatric Subjects
RandomizedSequentialQuadruple-blindPrevention
Summary
The purpose of this study is to compare the efficacy and safety of rimegepant to placebo as a preventative treatment for migraine in children and adolescents ≥ 6 to \<18 years with episodic migraine.
Timeline
- Start
- 2022-02-28
- Primary completion
- 2031-11-29
- Completion
- 2032-11-27
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Rimegepant | Small molecule | 50 mg | Oral |
| Comparator | Rimegepant | Small molecule | 75 mg | Oral |